Dimitrios Fotis1, Michael Doukas2, Bas Pl Wijnhoven3, Paul Didden1, Katharina Biermann2, Marco J Bruno1, Arjun D Koch1. 1. Department of Gastroenterology and Hepatology, Erasmus MC - University Medical Center, Rotterdam, the Netherlands. 2. Department of Pathology, Erasmus MC - University Medical Center, Rotterdam, the Netherlands. 3. Department of Surgery, Erasmus MC - University Medical Center, Rotterdam, the Netherlands.
Abstract
BACKGROUND: Due to the high mortality and morbidity rates of esophagectomy, endoscopic mucosal resection (EMR) is increasingly used for the curative treatment of early low risk Barrett's adenocarcinoma. OBJECTIVE: This retrospective cohort study aimed to assess the prevalence of lymph node metastases (LNM) in submucosal (T1b) esophageal adenocarcinomas (EAC) in relation to the absolute depth of submucosal tumor invasion and demonstrate the efficacy of EMR for low risk (well and moderately differentiated without lymphovascular invasion) EAC with sm1 invasion (submucosal invasion ≤500 µm) according to the Paris classification. METHODS: The pathology reports of patients undergoing endoscopic resection and surgery from January 1994 until December 2013 at one center were reviewed and 54 patients with submucosal invasion were included. LNM were evaluated in surgical specimens and by follow up examinations in case of EMR. RESULTS: No LNM were observed in 10 patients with sm1 adenocarcinomas that underwent endoscopic resection. Three of them underwent supplementary endoscopic eradication therapy with a median follow up of 27 months for patients with sm1 tumors. In the surgical series two patients (29%) with sm1 invasion according to the pragmatic classification (subdivision of the submucosa into three equal thirds), staged as sm2-3 in the Paris classification, had LNM. The rate of LNM for surgical patients with low risk sm1 tumors was 10% according to the pragmatic classification and 0% according to Paris classification. CONCLUSION: Different classifications of the tumor invasion depth lead to different LNM risks and treatment strategies for sm1 adenocarcinomas. Patients with low risk sm1 adenocarcinomas appear to be suitable candidates for EMR.
BACKGROUND: Due to the high mortality and morbidity rates of esophagectomy, endoscopic mucosal resection (EMR) is increasingly used for the curative treatment of early low risk Barrett's adenocarcinoma. OBJECTIVE: This retrospective cohort study aimed to assess the prevalence of lymph node metastases (LNM) in submucosal (T1b) esophageal adenocarcinomas (EAC) in relation to the absolute depth of submucosal tumor invasion and demonstrate the efficacy of EMR for low risk (well and moderately differentiated without lymphovascular invasion) EAC with sm1 invasion (submucosal invasion ≤500 µm) according to the Paris classification. METHODS: The pathology reports of patients undergoing endoscopic resection and surgery from January 1994 until December 2013 at one center were reviewed and 54 patients with submucosal invasion were included. LNM were evaluated in surgical specimens and by follow up examinations in case of EMR. RESULTS: No LNM were observed in 10 patients with sm1adenocarcinomas that underwent endoscopic resection. Three of them underwent supplementary endoscopic eradication therapy with a median follow up of 27 months for patients with sm1tumors. In the surgical series two patients (29%) with sm1 invasion according to the pragmatic classification (subdivision of the submucosa into three equal thirds), staged as sm2-3 in the Paris classification, had LNM. The rate of LNM for surgical patients with low risk sm1tumors was 10% according to the pragmatic classification and 0% according to Paris classification. CONCLUSION: Different classifications of the tumor invasion depth lead to different LNM risks and treatment strategies for sm1adenocarcinomas. Patients with low risk sm1adenocarcinomas appear to be suitable candidates for EMR.
Entities:
Keywords:
Early Barrett’s cancer; Paris classification; endoscopic mucosal resection; lymph node metastases; sm1 esophageal adenocarcinoma; submucosal invasion
Authors: Andrew P Barbour; Mark Jones; Ian Brown; David C Gotley; Ian Martin; Janine Thomas; Andrew Clouston; B Mark Smithers Journal: Ann Surg Oncol Date: 2010-03-27 Impact factor: 5.344
Authors: Marinke Westerterp; Linetta B Koppert; Christianne J Buskens; Hugo W Tilanus; Fiebo J W ten Kate; Jacques J H G M Bergman; Peter D Siersema; Herman van Dekken; Jan J B van Lanschot Journal: Virchows Arch Date: 2005-04-19 Impact factor: 4.064
Authors: Giuseppe Portale; Jeffrey A Hagen; Jeffrey H Peters; Linda S Chan; Steven R DeMeester; Tasha A K Gandamihardja; Tom R DeMeester Journal: J Am Coll Surg Date: 2006-04 Impact factor: 6.113
Authors: Jessica M Leers; Steven R DeMeester; Arzu Oezcelik; Nancy Klipfel; Shahin Ayazi; Emmanuele Abate; Jörg Zehetner; John C Lipham; Linda Chan; Jeffrey A Hagen; Tom R DeMeester Journal: Ann Surg Date: 2011-02 Impact factor: 12.969
Authors: P Thomas; C Doddoli; P Neville; J Pons; P Lienne; R Giudicelli; M Giovannini; J F Seitz; P Fuentes Journal: Eur J Cardiothorac Surg Date: 1996 Impact factor: 4.191
Authors: Christianne J Buskens; Marinke Westerterp; Sjoerd M Lagarde; Jacques J G H M Bergman; Fiebo J W ten Kate; J Jan B van Lanschot Journal: Gastrointest Endosc Date: 2004-11 Impact factor: 9.427
Authors: Rami J Badreddine; Ganapathy A Prasad; Jason T Lewis; Lori S Lutzke; Lynn S Borkenhagen; Kelly T Dunagan; Kenneth K Wang Journal: Clin Gastroenterol Hepatol Date: 2009-11-27 Impact factor: 11.382
Authors: Hendrik Manner; Andrea May; Oliver Pech; Liebwin Gossner; Thomas Rabenstein; Erwin Günter; Michael Vieth; Manfred Stolte; Christian Ell Journal: Am J Gastroenterol Date: 2008-09-10 Impact factor: 10.864
Authors: Annieke W Gotink; Fiebo Jc Ten Kate; Michael Doukas; Bas Pl Wijnhoven; Marco J Bruno; Leendert Hj Looijenga; Arjun D Koch; Katharina Biermann Journal: United European Gastroenterol J Date: 2018-12-06 Impact factor: 4.623
Authors: H T Künzli; K Belghazi; R E Pouw; S L Meijer; C A Seldenrijk; Blam Weusten; Jjghm Bergman Journal: United European Gastroenterol J Date: 2018-01-29 Impact factor: 4.623